AimTo compare the efficacy of everolimus-eluting versus sirolimus-eluting stents in patients with coronary artery disease.MethodsBy searching Medline(1960～2012.1) , CENTRAL（the Cochrane central register of controlled trials, 1989～2012.1）, EMBASE(1980～2012.1), CNKI（1979～2012.1）databases, the open published randomized controlled trials (RCT) about the efficacy of everolimus-eluting versus sirolimus-eluting stents in patients with coronary artery disease was calculated by statistic software Stata11.0.The relative risk (RR) was used as the effect size to compare the events occurred during the follow-up period between the two groups.ResultsSix trials including a total of 5196 patients were analyzed in this study.No statistical difference of major cardiac adverse events (death/ myocardial infarction) (RR=1.00, 95%CI:0.84～1.17,P=0.96), definite stents thrombosis(RR=0.53,95%CI:0.24～1.16,P=0.11) and revascularization (RR=0.88,95%CI:0.70～1.09,P=0.24) were found in this meta-analysis, respectively.ConclusionsThis meta-analysis did not demonstrate significant statistical difference in terms of efficacy and safety between everolimus-eluting and sirolimus-eluting stents in patients with coronary artery disease.